EuroBiotech: More articles of note


> Servier secured an option on Oncodesign’s LRRK2 Parkinson’s disease program. Oncodesign will take the program up to the receipt of IND status, at which point Servier will decide whether to pick up the candidate. Statement 

> FDA cleared Genfit to start a phase 2 trial of elafibranor in pediatric NASH patients. Release  

> ProQR dosed the first patient in its phase 1/2 trial of QR-421a in patients with Usher syndrome type 2. Statement  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Erytech confirmed it is on track to deliver interim data from its phase 3 pancreatic cancer trial in the first half of next year, despite taking longer than expected to get clearance to enroll patients in the U.S. Faster-than-expected enrollment in Europe has mitigated the effect of the delay. Release 

> Shares in GeNeuro jumped around 30% following the release of more data from its phase 2b multiple sclerosis trial. The stock is still well down on the highs it hit before a clinical setback in 2017. Statement 

> Herantis Pharma raised €5.8 million ($6.6 million). The Finnish drug developer will use the money to prepare for phase 2 and 3 trials of its treatments for lymphedema and Parkinson’s disease. Release 

Suggested Articles

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.

The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.